好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurologists’ Therapeutic Inertia in the Management of Generalized Myasthenia Gravis
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (11:45 AM-12:45 PM)
11-012
The study aim was to assess neurologists’ therapeutic inertia (TI) in generalized Myasthenia Gravis (gMG).
Limited information is available on how neurologists make therapeutic decisions in gMG, especially now that new treatments with different mechanisms of action, administration, and safety profiles are approved.
An online, cross-sectional study was conducted in collaboration with the Spanish Society of Neurology in April-July, 2024. Neurologists answered a survey of demographic characteristics, professional background, behavioral traits, and simulated case scenarios. TI score was defined as the number of simulated case scenarios that resulted in a lack of initiation/intensification to more efficacious treatments when therapeutic goals were unmet [meaning an increase in Myasthenia Gravis Activities of Daily Living (MG-ADL) scale of at least 1 point]. Scenarios included: four treated class IIa/IIb patients with limb/bulbar symptom worsening, one naïve patient, one rapidly progressing patient, and one with ocular symptom worsening. Relationships between TI presence and neurologists’ characteristics were assessed through Chi square test and Mann-Whitney U test.

A total of 149 neurologists were included (mean age [SD]: 39.0±9.4 years, 54.3% male, median experience managing gMG [IQR]: 7 [3-15] years; 32.2% fully dedicated to gMG). Median gMG patients attended per month was 10 (IQR: 5-20). A proportion of 34.9% participants reported using minimum symptom expression to guide treatment decisions.

Overall, 79.9% of participants (n=119/149) presented TI in at least 2 out of 7 scenarios. The mean (SD) TI score was 3.7 (2.1). Lower perceived ease of use of new targeted treatments, lower organizational support for the introduction of these new therapies, and higher overall resistance to change behavior were related to TI presence.
TI managing gMG is a common phenomenon in this new treatment context. Identifying it and implementing specific intervention strategies may be critical to avoid suboptimal treatment decisions and improve patient care.
Authors/Disclosures
Rocío Gómez, Other (Roche Farma S.A.)
PRESENTER 		Ms. Gómez has received personal compensation for serving as an employee of Roche Farma Spain, Medical Department.
Gerardo Gutierrez, MD (Hospital Universitario Infanta Sofía) Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. An immediate family member of Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharmamar. An immediate family member of Dr. Gutierrez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. An immediate family member of Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol, Myers, Squibb. An immediate family member of Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra-Zeneca. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra-Zeneca. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson&Johnson. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Gutierrez has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Gutierrez has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Gutierrez has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alter.
Javier Sotoca Fernandez Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Adrian Ares-Luque, MD Dr. Ares-Luque has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Ares-Luque has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
Ramon Villaverde Gonzalez Ramon Villaverde Gonzalez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Ramon Villaverde Gonzalez has received research support from Roche.
Virginia Reyes Garrido, Jr., MD Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi . Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche . Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NOVARTIS . Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Ms. Reyes Garrido has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
Thais Armangue, MD (IDIBAPS-HClinic) Dr. Armangue has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Armangue has received research support from ISCIII(Spanish institute of health) -PI21/00316, Marato TV3, La Caixa Research Foundadion, Pablove Foundation (689368), Torrons Vicens Foundation (PFNR0144), 2021 Invest AEP.
Luis Querol, MD, PhD (Hospital de la Santa Creu i Sant Pau) Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. The institution of Dr. Querol has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Querol has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ArgenX. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dianthus. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avilar. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocryst. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KPL. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lycia. The institution of Dr. Querol has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Querol has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Querol has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Querol has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Querol has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Querol has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Grifols. The institution of Dr. Querol has received research support from GBS-CIDP Foundation International. The institution of Dr. Querol has received research support from Grifols. The institution of Dr. Querol has received research support from ISCIII. The institution of Dr. Querol has received research support from CIBERER. The institution of Dr. Querol has received research support from UCB. The institution of Dr. Querol has received research support from ArgenX.
Elisa Salas Alonso Elisa Salas Alonso has nothing to disclose.
Paola Diaz, MD Mrs. Diaz has nothing to disclose.
Jorge Maurino Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.
Elena Cortes-Vicente (Hospital de la Santa Creu i Sant Pau) Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Elena Cortes-Vicente has received research support from UCB Pharma. The institution of Elena Cortes-Vicente has received research support from Instituto de Salud Carlos III (España).